PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2022 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.



Wednesday, August 17th

7:00 - 8:00 AM
INTRODUCTION TO A TREATMENT FOR ADULTS WITH ACUTE HEPATIC PORPHYRIA, INCLUDING ACUTE INTERMITTENT PORPHYRIA (SPONSORED BY ALNYLAM PHARMACEUTICALS)
Chicago Ballroom VI

Join Alnylam Pharmaceuticals for a presentation on a treatment for adults with acute hepatic porphyria (AHP) – including acute intermittent porphyria (AIP). AHP is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks. The cardinal symptom of an AHP attack is severe, diffuse abdominal pain. Presented by Dr. Ilene Weitz, this presentation will discuss a range of topics, including: • AHP disease overview and pathophysiology • Introduction to AHP treatment • Mechanism of Action • Efficacy and safety results from the Phase 3 Study and open-label extension Please join Alnylam Pharmaceuticals and Dr. Ilene Weitz, Professor of Clinical Medicine at the University of Southern California, to learn more about this treatment for adults with acute hepatic porphyria (AHP). Breakfast will be provided for attendees. This presentation is intended for US Healthcare Professionals only and no continuing education credits will be provided.


NOVEL INVESTIGATIONAL APPROACHES FOR HEMOPHILIA MANAGEMENT (SPONSORED BY SANOFI)
Chicago Ballroom IX-X

The symposium Novel Investigational Approaches for Hemophilia Management, organized by Sanofi, is intended for clinical and research experts in thrombosis, hemostasis, and vascular biology. Given the rapidly evolving therapeutic landscape in hemophilia management, there is a need for education on emerging treatments with novel mechanisms of action (MOA) and mechanisms of extension (MOE). The symposium will be presented in three parts: • Part 1 will provide a brief overview of current hemophilia management and unmet needs • Part 2 will describe the investigational molecule efanesoctocog alfa, with an MOE that overcomes the VWF-imposed half-life ceiling for FVIII replacement, and an overview of its clinical trial program • Part 3 will present the MOA of the investigational siRNA molecule fitusiran, and will conclude with an overview of its clinical trial program.

8:15 - 9:15 AM
BLEEDING: NOT OTHERWISE SPECIFIED (B-DUC)
Chair/Organizer: Yasmina Abajas, Maria Santaella
Sheraton Ballroom I-III
NOVEL TARGETS AND NOVEL USES FOR ANTICOAGULATION
Chair/Organizer: Vinai Bhagirath, Julie Jaffray
Sheraton Ballroom IV-V
QUALITY ASSURANCE IN THE HEMOSTASIS LABORATORY
Chair/Organizer: Katrien Devreese, Kristi Smock
Chicago Ballroom VII
9:15 - 10:00 AM
POSTERS/EXHIBITS/BREAK
Riverwalk AB
10:00 - 11:00 AM
SHORT TALKS - BLEEDING II
Chair/Organizer: Robert Sidonio, Yasmina Abajas
Sheraton Ballroom I-III

SHORT TALKS - PLATELETS AND VESSELS
Chair/Organizer: Peter Kouides, Brett Grieb
Chicago Ballroom VII

SHORT TALKS - THROMBOSIS CLINICAL AND SCIENCE
Chair/Organizer: Katrien Devreese, Shreya Agarwal
Sheraton Ballroom IV-V
11:05 - 12:20 PM
DIVERSITY, EQUITY, AND INCLUSION
Chair/Organizer: Cathy Hayward, Robert Sidonio
Sheraton Ballroom IV-V
12:35 - 1:35 PM
GENE THERAPY ELIGIBILITY: DELINEATING DIFFERENCES FROM CLINICAL TRIAL TO CLINICAL PRACTICE (SPONSORED BY CSL BEHRING MEDICAL AFFAIRS)
Chicago Ballroom IX-X

Join us and engage in a robust dialogue covering clinical and psychosocial considerations for gene therapy. This panel discussion, led by speakers from multidisciplinary teams will address topics such as: 1) Determining patient eligibility, insights from clinical trial to apply to clinical practice 2) Addressing liver health considerations and evaluation for referrals to a partnering hepatologist 3) Assessing eligibility based on lifestyle screening, patient expectations and commitment of therapy MODERATOR: Michael Recht, MD, PhD, MBA is the Chief Science Officer, American Thrombosis and Hemostasis Network; Professor of Clinical Pediatrics at Yale University School of Medicine SPEAKER PANEL includes: Sabrina Farina, LMSW at UT Health Houston; Mark Reding, MD a Professor of Medicine & Center for Bleeding and Clotting Disorders Director at the University of Minnesota Medical Center and Bruce Luxon, MD, PhD who is a Chair of the Department of Medicine Chief of Service for the Department of Medicine at Georgetown University Hospital


PROPHYLAXIS IN PATIENTS WITH VON WILLEBRAND DISEASE: EXPERT PERSPECTIVES AND SHARED EXPERIENCES - (ORGANIZED BY MEDICOM WORLDWIDE, INC AND IS SUPPORTED BY AN EDUCATIONAL GRANT FROM TAKEDA PHARMACEUTICALS U.S.A., INC.)
Chair/Organizer: Robert Sidonio, Jr
Chicago Ballroom VI

We invite you to join us for a dynamic and interactive panel discussion focused on new advances in prophylaxis treatment for von Willebrand Disease (VWD) and data supporting emerging therapeutic strategies. Our panel will spend time addressing guidelines, treatment strategies, and patient management considerations. Come prepared with your questions for an engaging discussion.
Click Here to take the post survey.

1:50 - 3:20 PM
MANAGEMENT OF UNUSUAL SITE THROMBOSIS ACROSS THE AGE SPECTRUM
Chair/Organizer: Julie Jaffray, Anne Rose
Sheraton Ballroom IV-V
NEW THERAPIES FOR BLEEDING DISORDERS
Chair/Organizer: Robert Sidonio, Michael Recht
Sheraton Ballroom I-III
PATHOGENESIS AND LABORATORY DIAGNOSIS OF PLATELET PROTHROMBOTIC STATES
Chair/Organizer: Cathy Hayward, Peter Kouides
Chicago Ballroom VII
3:20 - 4:05 PM
POSTERS/EXHIBITS/BREAK
Riverwalk AB
4:05 - 5:35 PM
HEALTH AND WELLNESS IN HEMOSTASIS AND THROMBOSIS
Chair/Organizer: Lena Volland, Michael Recht
Sheraton Ballroom I-III
IMPROVING THROMBOPHILIA AND BLEEDING DISORDER INVESTIGATIONS
Chair/Organizer: Karen Moser, Marian Rollins-Raval
Chicago Ballroom VII
NOVEL HEMOSTASIS MECHANISMS
Chair/Organizer: Meera Chitlur, Bhavya Doshi
Sheraton Ballroom IV-V
5:35 - 6:20 PM
POSTERS/EXHIBITS/BREAK
Riverwalk AB
6:20 - 7:35 PM
FOCUS ON FACTOR(SPONSORED BY SANOFI)
Chicago Ballroom IX-X

Treating hemophilia is often about balancing clinical needs with the lifestyle of each patient. Please join our upcoming symposium, Focus on Factor, at this year’s Thrombosis & Hemostasis Summit of North America (THSNA). During this time, Joanna Davis, MD and Guy Young, MD will share clinical data on treatment options of hemophilia A and hemophilia B. Q&A will follow the presentation.


IMMUNE THROMBOCYTOPENIA: EXPERT GUIDANCE TO INTEGRATE EMERGING THERAPIES INTO CLINICAL PRACTICE (SPONSORED BY CLINICAL CARE OPTIONS, LLC)
Chicago Ballroom VI

This 1.0-hour, CME-certified live satellite symposium will feature expert faculty presentations and discussions on integrating established and emerging therapies into the clinical management of immune thrombocytopenia (ITP). Topics that will be discussed will include treatment considerations for patients who are newly diagnosed with ITP, strategies for the optimal selection and sequencing of therapies for patients with progressing ITP, and the integration of novel and emerging therapies into the treatment of ITP. The faculty presentations and discussions also will feature expert guidance on the application of current clinical algorithms and evidence-based guidelines to the management of steroid-unresponsive ITP and considerations for treating ITP in special patient populations, such as children and those with chronic liver disease. These presentations will highlight key abstracts presented at THSNA 2022. Of importance, the faculty presenters will have the opportunity to engage in a lively panel discussion while answering pressing questions from the audience.